Amgen cash flow statement

In fiscal 2025, Amgen's operations generated $9.96bn of cash; it spent $1.86bn on capital projects, leaving free cash flow of $8.10bn. It returned $5.12bn in dividends.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Amgen: cash flow statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	6.3	5.8	5.1	5.9	6.3	9.0	9.7	10.4	11.2	11.3	9.2	10.5	9.3	9.7	8.5	11.5	10.0	12.5
Depreciation and amortisation	1.0	1.0	1.1	1.1	1.3	2.1	2.1	2.1	2.0	1.9	2.2	3.6	3.4	3.4	4.1	5.6	5.2	2.7
Stock-based pay	0.3	0.4	0.3	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.5	0.5
Capital spending	0.5	0.6	0.6	0.7	0.7	0.7	0.6	0.7	0.7	0.7	0.6	0.6	0.9	0.9	1.1	1.1	1.9	2.3
Free cash flow	5.8	5.2	4.6	5.2	5.6	8.2	9.1	9.6	10.5	10.6	8.5	9.9	8.4	8.8	7.4	10.4	8.1	10.2
Free cash flow after stock pay	5.5	4.9	4.2	4.8	5.2	7.8	8.8	9.3	10.2	10.2	8.2	9.6	8.0	8.4	6.9	9.9	7.6	9.7
Dividends paid	0.0	0.0	0.5	1.1	1.4	1.9	2.4	3.0	3.4	3.5	3.5	3.8	4.0	4.2	4.6	4.8	5.1	5.3
Share buybacks	3.2	3.8	8.3	4.6	0.8	0.1	1.9	3.0	3.2	17.8	7.7	3.5	5.0	6.4	0.0	0.2	0.0	—

US$ millions unless shown otherwise. Fiscal quarters.

Amgen: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	3,571	4,771	1,391	2,280	4,684	1,603	2,189	4,002
Depreciation and amortisation	198	1,397	1,387	220	232	1,132	1,116	222
Stock-based pay	136	134	85	157	127	125	75	165
Capital spending	257	371	411	369	436	642	712	513
Free cash flow	3,314	4,400	980	1,911	4,248	961	1,477	3,489
Free cash flow after stock pay	3,178	4,266	895	1,754	4,121	836	1,402	3,324

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMGN vs GILD ABBV vs AMGN AMGN vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Amgen's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amgen.